Ocuphire Pharma Investor Presentation Deck

12 Safety Findings Nyxol + LDP Combination Was Well Tolerated with a Favorable Safety Profile • No serious AEs, almost all AEs were mild 0% headaches or brow aches reported for Nyxol+LDP arm ● ● ● ≤ 5% mild, transient conjunctival hyperemia AEs in Nyxol+LDP arm No change in distance vision for Nyxol + LDP arm 0% had ≤ 5 letter distance loss in photopic lighting Only 5% distance loss in mesopic lighting No change in IOP ● ● Source: VEGA-1 Study Results (Safety Population, n=150); Only a single subject difference between mITT (n=148) and PP population (n=147) Ocuphire PHARMA

View entire presentation